Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seltorexant in Major Depressive Disorder (MDD)
NCT07573176Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of seltorexant in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Apr 2026; status: recruiting.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07573176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07573176.